Blocking HER-2-Mediated Transformation with a Dominant Negative Form of HER-3
Abstract
Amplification of the HER-2 gene often leads to breast cancer by causing cells to make abnormally high levels of the wild-type HER-2 protein. Evidence now shows that the interaction between HER-2 and HER-3 leads to the constitutive activation of HER-2/HER-3 heterodimers in breast cancer cells with HER-2 gene amplification, and HER-2/HER-3 potently activates multiple signal transduction pathways involved in mitogenesis. This indicates that inhibition of the interaction between HER-2 and HER-3 may be an especially effective and unique strategy for blocking the effects of HER-2 in human breast cancer cells. Therefore, we constructed a bicistronic retroviral expression vector that codes for a dominant negative form of HER-3 that can inactivate the function of HER-2/HER-3.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2001
- Accession Number
- ADA397093
Entities
People
- Tracy G. Ram
Organizations
- Washington State University